Multi-specific antibodies

Delve into the world of Multi-specific antibodies in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Multi-specific antibodies to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Asymchem's Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility
Company

Asymchem’s Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility

Asymchem Laboratories (Tianjin) Co., Ltd. (SHE: 002821; HKG: 6821) announced that its Chemistry Macromolecule Base, located in the West District of the Tianjin Economic‑Technological Development Area (TEDA), completed a US…

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Qyuns Therapeutics' Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Qyuns Therapeutics’ Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment

CompanyDrug

Mabwell’s 6MW3511 Accepted by NMPA for Advanced Solid Tumor Treatment

CompanyDrug

Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052

Show More